Dawwas GK, et al. - Researchers performed this retrospective cohort analysis using Truven Health to investigate the link between cardiovascular diseases (CVD) and SGLT2 inhibitors vs sulfonylureas and dipeptidyl peptidase-4 (DPP4) inhibitors and to assess within-class impacts of SGLT2 inhibitors. Participants included new-users of SGLT2 inhibitors, sulfonylureas, or DPP-4 inhibitors. They observed a lower incidence of CVD was correlated with incident use of SGLT-2 inhibitors vs sulfonylurea and DPP-4 inhibitors. The observed consistency of these findings between dapagliflozin and canagliflozin implied that CVD reduction is a class effect for SGLT2 inhibitors. A lower risk of heart failure hospitalization was found to be related to SGLT2 inhibitors vs sulfonylureas and DPP-4 inhibitors. Also, SGLT2 inhibitors vs sulfonylureas were associated with lower risk of lower extremity amputation.